Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
P/E Ratio
--
P/B Ratio
1.18
Industry P/E
--
Debt to Equity
--
ROE
-3.24 %
ROCE
-323.8 %
Div. Yield
0 %
Book Value
0.81
EPS
-2.64
CFO
$-47.65 Mln
EBITDA
$-64.80 Mln
Net Profit
$-73.36 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Adial Pharmaceuticals (ADIL)
| -32.08 | -1.14 | -34.04 | -69.38 | -74.97 | -55.87 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Adial Pharmaceuticals (ADIL)
| -45.43 | -65.40 | -91.85 | 58.82 | -29.46 | -52.93 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist,... which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia. Address: 4870 Sadler Road, Glen Allen, VA, United States, 23060 Read more
CEO, President & Director
Mr. Cary John Claiborne MBA
CEO, President & Director
Mr. Cary John Claiborne MBA
Headquarters
Glen Allen, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Adial Pharmaceuticals Inc (ADIL) stood at $ 5 Mln as on 31-Dec-24
The share price of Adial Pharmaceuticals Inc (ADIL) is $0.69 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Adial Pharmaceuticals Inc (ADIL) has given a return of -74.97% in the last 3 years.
Adial Pharmaceuticals Inc (ADIL) has a market capitalisation of $ 5 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Adial Pharmaceuticals Inc (ADIL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Adial Pharmaceuticals Inc (ADIL) and enter the required number of quantities and click on buy to purchase the shares of Adial Pharmaceuticals Inc (ADIL).
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia. Address: 4870 Sadler Road, Glen Allen, VA, United States, 23060
The CEO & director of Mr. Cary John Claiborne MBA. is Adial Pharmaceuticals Inc (ADIL), and CFO & Sr. VP is Mr. Cary John Claiborne MBA.
There is no promoter pledging in Adial Pharmaceuticals Inc (ADIL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Adial Pharmaceuticals Inc (ADIL) | Ratios |
|---|---|
|
Return on equity(%)
|
-323.8
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Adial Pharmaceuticals Inc (ADIL) was $0 Mln.
$-0.03
(
